Importantly, the April 22, 2025 and May 22, 2025 cut-off dates are for those compounded products that are essentially a copy of an FDA-approved product
Aim for at least 8 glasses of water a day (more if tolerated)
Keywords: case report, cutaneous lupus erythematosus, discoid lupus erythematosus (dle), glp-1 receptor agonist, semaglutide Introduction Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus erythematosus (CCLE), typically affecting women of childbearing age [1,2]
The main ingredient, Semaglutide, is a GLP-1 receptor agonist that supports appetite suppression, improved insulin sensitivity, and enhanced blood sugar regulation
Those modifications do not change what semaglutide does at the receptor